Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00047333 · ClinicalTrials.gov registry record · Phase 2
Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically Removed
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT00047333: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00047333 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 80 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00047333, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
Phase II trial to study the effectiveness of erlotinib in treating patients who have liver cancer that cannot be surgically removed. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- DRUG erlotinib hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2002-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00047333
The ClinicalTrials.gov registry entry for NCT00047333 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00047333 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00047333 about?
NCT00047333 is a clinical study titled "Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically Removed". Phase II trial to study the effectiveness of erlotinib in treating patients who have liver cancer that cannot be surgically removed. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth
What is the current status of trial NCT00047333?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2002-08.
What interventions are being tested in trial NCT00047333?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), erlotinib hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00047333?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.